Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

The Lancet. Oncology - 1 Dec 2015

Grönberg Henrik, Adolfsson Jan, Aly Markus, Nordström Tobias, Wiklund Peter, Brandberg Yvonne, Thompson James, Wiklund Fredrik, Lindberg Johan, Clements Mark, Egevad Lars, Eklund Martin

Abstract excerpt

BACKGROUND: The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Decision Support Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Early Detection of Cancer

Share to Kallikreins

Share to Neoplasm Grading

Share to Prostate-Specific Antigen

Share to ROC Curve

Share to Sweden

Source

Identifiers

PMID: 26563502
DOI: 10.1016/S1470-2045(15)00361-7

Genes

MSMB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.PMID 26563502Read ↗

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.Semantic proximity Read ↗

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.Semantic proximity Read ↗

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.Semantic proximity Read ↗

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.Semantic proximity Read ↗

Assessment of a Polygenic Risk Score in Screening for Prostate CancerSemantic proximity Read ↗

Prostate cancer risk-stratification using proteomic estimation of KLK3 improves accuracy in screening applications: a population-based cohort study in the UK BiobankSemantic proximity Read ↗

Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk.Semantic proximity Read ↗

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.Semantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

Multiple newly identified loci associated with prostate cancer susceptibility.Semantic proximity Read ↗

The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.Semantic proximity Read ↗

Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.